Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000069.xml
Download PDF
Semin Liver Dis 2018; 38(01): 014-020
DOI: 10.1055/s-0037-1618587
DOI: 10.1055/s-0037-1618587
Review Article
Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?
Grant Support Dr. Ajmera is supported by the Advanced/Transplant Hepatology Fellowship and the Alan Hofmann Clinical and Translational Research Award from the AASLD Foundation. Dr. Loomba is supported by NIH/R01-DK106419–02.
Further Information
Publication History
Publication Date:
22 February 2018 (online)
Abstract
Ultrasound and magnetic resonance (MR)-based elastography have demonstrated excellent performance for noninvasive staging of fibrosis in patients with nonalcoholic fatty liver disease (NAFLD); however, their ability to differentiate isolated fatty liver from nonalcoholic steatohepatitis (NASH) is unclear. In this review, the authors provide background on elastography and review the ability of elastography to discriminate between isolated steatosis and NASH. Studies with available data on the diagnosis of NASH histology are limited to vibration-controlled transient elastography and MR elastography. A wide range of optimal cutoffs for the diagnosis of NASH are reported and likely depend on the prevalence of advanced fibrosis in the study population. MR elastography has good performance characteristics for identifying patients with any fibrosis who are at greatest risk of disease-related morbidity. Currently, neither modality can reliably discriminate NASH from simple steatosis. Novel multiparametric MR imaging and elastography are emerging and may help detect presence of NASH in the future.
-
References
- 1 Williams CD, Stengel J, Asike MI. , et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140 (01) 124-131
- 2 Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10 (11) 686-690
- 3 Younossi ZM, Blissett D, Blissett R. , et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016; 64 (05) 1577-1586
- 4 Browning JD, Szczepaniak LS, Dobbins R. , et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40 (06) 1387-1395
- 5 Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13 (04) 643-54.e1 , 9, quiz e39–e40
- 6 Merriman RB, Ferrell LD, Patti MG. , et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44 (04) 874-880
- 7 Regev A, Berho M, Jeffers LJ. , et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97 (10) 2614-2618
- 8 Poynard T, Ratziu V, Charlotte F. , et al; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34
- 9 Guha IN, Parkes J, Roderick P. , et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47 (02) 455-460
- 10 Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004; 40 (01) 46-54
- 11 Hui JM, Farrell GC, Kench JG, George J. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology 2004; 39 (05) 1458-1459
- 12 Mitry RR, De Bruyne R, Quaglia A, Hughes RD, Dhawan A. Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers. Hepatology 2007; 46 (06) 2047-2048 , author reply 2048
- 13 Ajmera V, Perito ER, Bass NM. , et al; NASH Clinical Research Network. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology 2017; 65 (01) 65-77
- 14 Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50 (04) 1072-1078
- 15 Cusi K, Chang Z, Harrison S. , et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2014; 60 (01) 167-174
- 16 Permutt Z, Le TA, Peterson MR. , et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012; 36 (01) 22-29
- 17 Tang A, Tan J, Sun M. , et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013; 267 (02) 422-431
- 18 Idilman IS, Aniktar H, Idilman R. , et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013; 267 (03) 767-775
- 19 Park CC, Nguyen P, Hernandez C. , et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 2017; 152 (03) 598-607.e2
- 20 Imajo K, Kessoku T, Honda Y. , et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 2016; 150 (03) 626-637.e7
- 21 Sandrin L, Fourquet B, Hasquenoph JM. , et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29 (12) 1705-1713
- 22 European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63 (01) 237-264
- 23 Dietrich CF, Bamber J, Berzigotti A. , et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall Med 2017; 38 (04) e16-e47
- 24 Arena U, Vizzutti F, Corti G. , et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47 (02) 380-384
- 25 Millonig G, Friedrich S, Adolf S. , et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol 2010; 52 (02) 206-210
- 26 Millonig G, Reimann FM, Friedrich S. , et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008; 48 (05) 1718-1723
- 27 Lemoine M, Shimakawa Y, Njie R. , et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. Aliment Pharmacol Ther 2014; 39 (02) 188-196
- 28
Bardou-Jacquet E,
Legros L,
Soro D.
, et al. Effect of alcohol consumption on liver stiffness measured by transient elastography.
World J Gastroenterol 2013; 19 (04) 516-522
MissingFormLabel
- 29 Petta S, Wong VW, Cammà C. , et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology 2017; 65 (04) 1145-1155
- 30 Arena U, Vizzutti F, Abraldes JG. , et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57 (09) 1288-1293
- 31 Wong VW, Vergniol J, Wong GL. , et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51 (02) 454-462
- 32 Gaia S, Carenzi S, Barilli AL. , et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54 (01) 64-71
- 33 Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48 (05) 835-847
- 34 Castéra L, Foucher J, Bernard PH. , et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51 (03) 828-835
- 35 Vuppalanchi R, Siddiqui MS, Van Natta ML. , et al; NASH Clinical Research Network. Performance characteristics of vibration-controlled transient elastography for evaluation of non-alcoholic fatty liver disease. Hepatology 2017;
- 36 Wong VW, Vergniol J, Wong GL. , et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107 (12) 1862-1871
- 37 Bota S, Herkner H, Sporea I. , et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int 2013; 33 (08) 1138-1147
- 38 Cassinotto C, Boursier J, de Lédinghen V. , et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology 2016; 63 (06) 1817-1827
- 39 Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging 2013; 37 (03) 544-555
- 40 Singh S, Venkatesh SK, Loomba R. , et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol 2016; 26 (05) 1431-1440
- 41 Singh S, Venkatesh SK, Wang Z. , et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 2015; 13 (03) 440-451.e6
- 42 Salameh N, Larrat B, Abarca-Quinones J. , et al. Early detection of steatohepatitis in fatty rat liver by using MR elastography. Radiology 2009; 253 (01) 90-97
- 43 Georges PC, Hui JJ, Gombos Z. , et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 293 (06) G1147-G1154
- 44 Fracanzani AL, Valenti L, Bugianesi E. , et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48 (03) 792-798
- 45 Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259 (03) 749-756
- 46 Kleiner DE, Brunt EM, Van Natta M. , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (06) 1313-1321
- 47 Loomba R, Wolfson T, Ang B. , et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014; 60 (06) 1920-1928
- 48 Chen J, Yin M, Talwalkar JA. , et al. Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity. Radiology 2017; 283 (02) 418-428
- 49 Palmeri ML, Wang MH, Rouze NC. , et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55 (03) 666-672
- 50 Loomba R, Cui J, Wolfson T. , et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol 2016; 111 (07) 986-994
- 51 Pavlides M, Banerjee R, Tunnicliffe EM. , et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int 2017; 37 (07) 1065-1073
- 52 Yin M, Glaser KJ, Manduca A. , et al. Distinguishing between hepatic inflammation and fibrosis with MR elastography. Radiology 2017; 284 (03) 694-705
- 53 Allen AM, Yin M, Venkatesh SK. , et al. SAT-464-Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis. J Hepatol 2017; 66 (01) 659-660
- 54 Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. ; American Association for the Study of Liver Diseases; United States Food and Drug Administration; Food and Drug Administration Joint Workshop. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Hepatology 2015; 61 (04) 1392-1405
- 55 Noureddin M, Lam J, Peterson MR. , et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013; 58 (06) 1930-1940
- 56 Patel J, Bettencourt R, Cui J. , et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2016; 9 (05) 692-701
- 57 Boursier J, Vergniol J, Guillet A. , et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol 2016; 65 (03) 570-578
- 58 Patel NS, Hooker J, Gonzalez M. , et al. Weight loss decreases magnetic resonance elastography estimated liver stiffness in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2017; 15 (03) 463-464
- 59 Loomba R, Sirlin CB, Ang B. , et al; San Diego Integrated NAFLD Research Consortium (SINC). Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015; 61 (04) 1239-1250
- 60 Cui J, Philo L, Nguyen P. , et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2016; 65 (02) 369-376
- 61 Angulo P, Kleiner DE, Dam-Larsen S. , et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149 (02) 389-97.e10
- 62 Ekstedt M, Hagström H, Nasr P. , et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61 (05) 1547-1554
- 63 Kleiner D, Belt PH, Wilson L. , et al. Diagnostic pattern and disease activity are related to disease progression and regression in nonalcoholic fatty liver disease abstracts 37. Hepatology 2016; 64: 1-136
- 64 Decaris ML, Li KW, Emson CL. , et al. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood. Hepatology 2017; 65 (01) 78-88
- 65 Lee HW, Park SY, Kim SU. , et al. Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease. PLoS One 2016; 11 (06) e0157358